Affimed(US:AFMD) Newsfilter·2024-05-23 21:05Core Insights - The combination of AFM24 and atezolizumab in patients with metastatic EGFR wild-type NSCLC showed a disease control rate of 73.3% with 4 objective responses, including 1 complete response and 3 partial responses [1][2] - The median progression-free survival for the treatment was reported at 5.9 months, with 3 of the 4 responses ongoing as of the March 18, 2024 data cut-off [1][2] - The study will present its findings at the ASCO annual meeting on June 1, 2024, and a conference call will be held the same day to discuss updated results [1][4][5] Study Details - The AFM24-102 study involved 17 patients with EGFR wild-type NSCLC, of which 15 were evaluable for response [2] - All responders had previously shown resistance to checkpoint inhibitor treatments, indicating the potential of AFM24 combined with atezolizumab to enhance the cancer-immunity cycle [2][3] - The study aims to enroll up to 40 patients in the EGFR wild-type cohort and 25 patients in the EGFR mutant cohort [3] Treatment and Safety - AFM24 and atezolizumab were administered at their respective single-agent doses, and the treatment was well tolerated among heavily pretreated patients [3] - Side effects were consistent with known safety profiles, primarily mild to moderate infusion-related reactions and transient increases in liver enzymes [3] Company Overview - Affimed N.V. is a clinical-stage immuno-oncology company focused on leveraging the innate immune system to combat cancer through its proprietary ICE® platform [7][8] - The company is committed to developing therapies that enable a tumor-targeted approach to treat various hematologic and solid tumors [8]